The SpIDnet (Streptococcus pneumoniae Invasive Disease network) aimed to strengthen
surveillance for invasive pneumococcal disease (IPD) in all age groups. SpIDnet includes
multicentre studies to measure the effectiveness (VE) of pneumococcal vaccines and impact of vaccination programmes in Europe.
Streptococcus pneumoniae infection constitutes a major public health problem worldwide, with almost 100 serotypes identified so far. Invasive pneumococcal disease (IPD) incidence rates vary across countries, depending on clinical practices, organisation of health care and
Two major groups of pneumococcal vaccines are currently available: polysaccharide vaccines, i.e. 23-valent vaccine (PPV23) and conjugate vaccines (PCV). Starting in 2009, conjugate vaccines covering 10 and 13 serotypes have replaced the 7-valent vaccine in most European countries. New vaccines covering 15 and 20 serotypes will be gradually included in the vaccination programmes following authorisation in Europe.
Development of protocols
Development of generic protocols for IPD surveillance, pneumococcal vaccines’ effectiveness studies (indirect cohort method, cohort) and for impact of vaccination programmes studies.
Coordination of networks
Coordination of multicentre, multicountry surveillance and research networks: review of protocols, organisation of scientific conferences and technical workshops
Pooled data analysis
Pooled analyses to provide pneumococcal vaccines’ effectiveness and population level impact estimates at the European level: data management, data validation, development of scripts, report writing, scientific communications.
Participation of global surveillance & research
Contributed to the global surveillance and research on pneumococcal diseases (PSERENADE).